Invention Grant
US08853398B2 Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b] pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound
有权
制备{4,6-二氨基-2- [1-（2-氟苄基）-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的方法及其纯化 作为药物活性化合物
![Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b] pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound](/docs/US/2014-10-07/US08853398B2/abs.jpg.600x600.jpg)
- Patent Title: Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b] pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound
- Patent Title (中): 制备{4,6-二氨基-2- [1-（2-氟苄基）-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的方法及其纯化 作为药物活性化合物
-
Application No.: US13945639Application Date: 2013-07-18
-
Publication No.: US08853398B2Publication Date: 2014-10-07
- Inventor: Franz-Josef Mais , Joachim Rehse , Winfried Joentgen , Konrad Siegel
- Applicant: Bayer Intellectual Property GmbH
- Applicant Address: DE Monheim
- Assignee: Bayer Intellectual Property GmbH
- Current Assignee: Bayer Intellectual Property GmbH
- Current Assignee Address: DE Monheim
- Agency: Buchanan Ingersoll & Rooney PC
- Priority: EP09177371 20091127
- Main IPC: C07D403/04
- IPC: C07D403/04 ; C07D487/04 ; C07D239/50 ; C07D239/48 ; C07D471/04 ; C07C325/02
![Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b] pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound](/abs-image/US/2014/10/07/US08853398B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to a process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate of the formula (I) and to a process for purifying the crude product of the compound of the formula (I) for use as pharmaceutically active compound, where, for purification, methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate sulphinyldimethane (1:1), i.e. a compound of the formula (II), is isolated as intermediate or is generated as intermediate in this purification process, if appropriate present in a mixture.
Public/Granted literature
Information query
